Maintenance Olaparib plus Bevacizumab for Newly Diagnosed High-Grade Ovarian Cancer: Second Progression-Free Survival

Conference Correspondent  - ESMO 2020

The phase 3 PAOLA/ENGOT-ov25 study assessed the outcomes of adding olaparib (OLA) to maintenance bevacizumab (BEV) after first-line platinum-based chemotherapy with BEV for patients with newly diagnosed high-grade ovarian cancer. The significant improvement associated with the addition of OLA in terms of progression-free survival (PFS) has been previously reported (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.49-0.72). However, in the initial report, second PFS (PFS2) data were not yet complete. The authors report the data here.

In this study, 537 patients were randomized to receive OLA (300 mg twice daily for 24 months) + BEV (15 mg/kg once every 3 weeks for 15 months), and 269 patients were randomized to receive placebo + BEV. These patients had already received first-line treatment of upfront or interval surgery and platinum-taxane–based chemotherapy plus at least 2 cycles of BEV. The randomization was stratified by tumor BRCA status and first-line treatment outcomes. PFS2 and time to second subsequent therapy (TSST) or death were secondary end points.

The median PFS2 was 36.5 months for the OLA + BEV arm and 32.6 months for the placebo + BEV arm (HR, 0.78; 95% CI, 0.64-0.95; P = .0125). There were also fewer events per patient in the OLA + BEV arm (48%) than the placebo + BEV arm (61%). In a subgroup analysis of patients by homologous recombination deficiency (HRD) status, OLA + BEV resulted in improved PFS2 over placebo + BEV for HRD-positive patients, regardless of whether those with tumor BRCA-mutated status were included in the analysis. For all HRD-positive patients, median PFS2 was 50.3 months with OLA + BEV versus 35.3 months for placebo + BEV (HR, 0.56; 95% CI, 0.41-0.77), and for the HRD-positive subgroup without tumor BRCA mutated, median PFS2 was 50.3 months for OLA + BEV versus 30.1 months for placebo + BEV (HR, 0.60; 95% CI, 0.38-0.96). For those with HRD-negative or unknown status, OLA + BEV and placebo + BEV resulted in similar median PFS2; 26.3 months and 28.1 months, respectively (HR, 0.98; 95% CI, 0.77-1.27).

The benefit of treatment with OLA + BEV was further supported by a statistically significant improvement in TSST. Median TSST for the OLA + BEV arm was 38.2 months versus 31.5 months for the placebo + BEV arm (HR, 0.78; 95% CI, 0.64-0.95; P = .0115). For the tumor BRCA mutated and the HRD-positive subgroups, OLA + BEV also resulted in an improved TSST, with corresponding HR values of 0.48 (95% CI, 0.31-0.75) and 0.48 (95% CI, 0.35-0.66) for these subgroups, respectively. However, for HRD-negative or unknown patients, there was not a significant difference in TSST (HR, 1.05; 95% CI, 0.82-1.36). No new safety signals have been detected in patients in the active arm with longer follow-up.

In summary, the addition of maintenance OLA + BEV provided benefit beyond initial progression, significantly improving PFS2, particularly in HRD-positive patients. This outcome was supported by a delay in TSST. Overall survival data will be provided at a later time, as they are still immature.

Reference

Abstract and Late-Breaking Oral Presentation LBA33. ESMO 2020. September 21, 2020. Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial.

Related Items
Olaparib Significantly Improves Survival in Men with Metastatic Prostate Cancer and BRCA Mutations
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in ESMO 2020
“Practice-Changing” Results Seen with Adjuvant Abemaciclib plus Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in ESMO 2020
Cabozantinib plus Nivolumab Offers New First-Line Treatment Option for Patients with Advanced Renal-Cell Carcinoma
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in ESMO 2020
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO 2020
Trabectedin/PLD versus Carboplatin/PLD in Recurrent Ovarian Cancer Progressing within 6-12 Months After Last Platinum Line
Conference Correspondent  published on September 23, 2020 in ESMO 2020
Safety and Efficacy of XMT-1536 in Ovarian Cancer: Subgroup Analysis from a Phase 1 Expansion Study
Conference Correspondent  published on September 23, 2020 in ESMO 2020
Real-World Data on Platinum Therapy in High-Grade Serous Ovarian Cancer Patients Progressing After PARP Inhibitor Treatment
Conference Correspondent  published on September 23, 2020 in ESMO 2020
Atezolizumab in Patients with Newly Diagnosed Stage III or Stage IV Ovarian Cancer
Conference Correspondent  published on September 23, 2020 in ESMO 2020
Mirvetuximab Soravtansine in Combination with Carboplatin and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on September 22, 2020 in ESMO 2020
Patient-Reported Outcomes in Patients Receiving Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Trial
Conference Correspondent  published on September 22, 2020 in ESMO 2020
Last modified: September 23, 2020